Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
HRID 125생성일: 2026년 10월 23일
2-Methyl-2H-pyrazol-3-ylamine → 8-(5-chloro-2-(1-methyl-1H-pyrazol-5-ylamino)pyridin-4-ylamino)-2-methyl-3,4-dihydroisoquinolin-1(2H)-one
https://huagongshe.com/ko/reaction/125
참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | 2-Methyl-2H-pyrazol-3-ylamine | HCID 136927 | — |
| 반응물 | 8-[(2,5-Dichloropyridin-4-yl)amino]-2-methyl-3,4-dihydroisoquinolin-1-one | HCID 86655137 | — |
| 시약 | Sodium t-butoxide | HCID 23676156 | — |
| 촉매 | Binap, (A+-)- | HCID 634876 | — |
| 촉매 | Bis(dibenzylideneacetone)palladium | HCID 9811564 | — |
| 용매 | 1,4-Dioxane | HCID 31275 | — |
| 생성물 | 8-(5-chloro-2-(1-methyl-1H-pyrazol-5-ylamino)pyridin-4-ylamino)-2-methyl-3,4-dihydroisoquinolin-1(2H)-one | HCID 44609040 | 26.93% |
반응 단계
8-(2,5-dichloropyridin-4-ylamino)-2-methyl-3,4-dihydroisoquinolin-1(2H)-one (100 mg, 0.31 mmol), 1-methyl-1H-pyrazol-5-amine (60.3 mg, 0.62 mmol), sodium 2-methylpropan-2-olate (44.7 mg, 0.47 mmol), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (38.7 mg, 0.06 mmol) and TRIS(DIBENZYLIDENEACETONE)DIPALLADIUM (28.4 mg, 0.03 mmol) were suspended in dioxane (2 mL) and sealed into a tube. The reaction was degased, purged with nitrogen and heated to 100 °C for 1 hour. Reaction was filtered, washed with CH2Cl2 and concentrated to dryness. The reaction mixture was purified by preparative HPLC using a Waters X-Bridge reverse-phase column (5 microns silica, 30 mm diameter, 150 mm length) and decreasingly polar mixtures of water (containing 0.2% ammonium carbonate) and acetonitrile as eluent. The fractions were evaporated to dryness to afford 8-(5-chloro-2-(1-methyl-1H-pyrazol-5-ylamino)pyridin-4-ylamino)-2-methyl-3,4-dihydroisoquinolin-1(2H)-one (32.0 mg, 26.9 %) as a white solid.
출처 및 근거
| 출처 데이터셋 | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-e45b32fa63b1416c9334b4592b5aba03 |
|---|
| 출처 메모 | 750 AstraZeneca ELN dataset |
|---|